Want to see REGN full AI Analyst Report?
Revenue by Segment
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which might need strategic adjustments.Net product revenue remains the largest but shows pronounced volatility tied to product mix shifts—EYLEA base is declining while EYLEA HD and newer launches buoy sales—creating lumpy quarters and near‑term downside from inventory and a temporary Limerick manufacturing interruption. Collaboration revenue has become an increasingly material and steady growth engine; management’s note that the Sanofi development balance will be repaid by end‑Q2 (with full profit share recognized from Q3) implies collaboration will drive cleaner upside going forward, even as legacy EYLEA faces competitive and pricing pressure.
Date | Other | Collaboration | Net Product |
|---|---|---|---|
Jun 30, 2026 | $193.30M | $2.46B | $1.64B |
Mar 31, 2026 | $171.00M | $1.90B | $1.53B |
Dec 31, 2025 | $238.00M | $1.97B | $1.68B |
Sep 30, 2025 | $198.00M | $1.97B | $1.59B |
Jun 30, 2025 | $183.90M | $1.86B | $1.63B |
Mar 31, 2025 | $81.90M | $1.53B | $1.42B |
Dec 31, 2024 | $179.40M | $1.61B | $2.00B |
Sep 30, 2024 | $114.20M | $1.66B | $1.95B |
Jun 30, 2024 | $104.50M | $1.52B | $1.92B |
Mar 31, 2024 | $116.90M | $1.27B | $1.76B |